Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
MYO-029
Accession Number
DB05915
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
Not Available
CAS number
Not Available

Pharmacology

Indication

Investigated for use/treatment in muscular dystrophy.

Pharmacodynamics
Not Available
Mechanism of action

MYO-029 is used to treat muscular dystrophy. It binds to and inhibit the activity of myostatin (growth and differentiation factor 8 or GDF-8), a protein that prevents skeletal muscle formation. Muscular dystrophy is characterized by a progressive wasting and weakening of muscle fibers. The disorder can be classified into six major types, all of which are inherited. The common feature of these disorders is absence of one of several proteins involved in linking F-actin (a muscle fiber component) to the sheath of tissue surrounding the fiber.

TargetActionsOrganism
UGrowth/differentiation factor 8Not AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with MYO-029.
AbituzumabThe risk or severity of adverse effects can be increased when MYO-029 is combined with Abituzumab.
AbrilumabThe risk or severity of adverse effects can be increased when MYO-029 is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with MYO-029.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with MYO-029.
AducanumabThe risk or severity of adverse effects can be increased when MYO-029 is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with MYO-029.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with MYO-029.
AlirocumabThe risk or severity of adverse effects can be increased when MYO-029 is combined with Alirocumab.
AmatuximabThe risk or severity of adverse effects can be increased when MYO-029 is combined with Amatuximab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, Flanigan KM, Pestronk A, Tawil R, Wolfe GI, Eagle M, Florence JM, King WM, Pandya S, Straub V, Juneau P, Meyers K, Csimma C, Araujo T, Allen R, Parsons SA, Wozney JM, Lavallie ER, Mendell JR: A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008 May;63(5):561-71. doi: 10.1002/ana.21338. [PubMed:18335515]
  2. Sunada Y: [Therapeutic strategies for muscular dystrophy by myostatin inhibition]. Rinsho Shinkeigaku. 2006 Nov;46(11):942-4. [PubMed:17432227]
  3. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS: Functional improvement of dystrophic muscle by myostatin blockade. Nature. 2002 Nov 28;420(6914):418-21. [PubMed:12459784]
External Links
PubChem Substance
347910311
Wikipedia
MYO-029

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedHealth Services ResearchHealthy Volunteers1
1, 2CompletedTreatmentBecker's Muscular Dystrophy (BMD) / Facioscapulohumeral Muscular Dystrophy / Limb-Girdle Muscular Dystrophies1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Transforming growth factor beta receptor binding
Specific Function
Acts specifically as a negative regulator of skeletal muscle growth.
Gene Name
MSTN
Uniprot ID
O14793
Uniprot Name
Growth/differentiation factor 8
Molecular Weight
42749.8 Da

Drug created on November 18, 2007 11:28 / Updated on December 02, 2019 07:16